1.Improvement of the quality standard for Kunxian capsules
Chunfang XU ; Zhexuan LI ; Luoying ZHOU ; Ni ZHANG ; Hong YANG ; Xia TAO
Journal of Pharmaceutical Practice 2022;40(2):152-156
Objective To improve the quality standards of Kunxian capsules (KC) and effectively control the product quality. Methods Triptolide, icariin and hypericin were used as the indicator components, to increase or improve the thin layer chromatography (TLC) identification methods of Kunming begonia, epimedium and dodder. Agilent ZORBA SB-C18 (4.6 mm×250 mm, 5 μm) as a chromatographic column, the HPLC method for the determination of triptolide was improved with acetonitrile-0.1% formic acid solution as the mobile phase and 220 nm as the detection wavelength. Results The spots in the TLC method of Kunming begonia, epimedium and dodder has strong specificity, good and clear separation of characteristic spots, negative and no interference. The quantitative analysis of the content of triptolide in KC showed that there is a good linear relationship (r=0.9995) between the mass concentration of triptolide and the peak area in the range of 40.16-502.00 μg/ml, the average recovery was 98.12%, RSD was 8.25%, and the accuracy was good. Conclusion The TLC identification method and HPLC method established in this experiment have strong specificity and good reproducibility, and can effectively control the quality of KC.
2.Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis
Zheng LIU ; Jianjun CHEN ; Lei CHENG ; Huabin LI ; Shixi LIU ; Hongfei LOU ; Jianbo SHI ; Ying SUN ; Dehui WANG ; Chengshuo WANG ; Xiangdong WANG ; Yongxiang WEI ; Weiping WEN ; Pingchang YANG ; Qintai YANG ; Gehua ZHANG ; Yuan ZHANG ; Changqing ZHAO ; Dongdong ZHU ; Li ZHU ; Fenghong CHEN ; Yi DONG ; Qingling FU ; Jingyun LI ; Yanqing LI ; Chengyao LIU ; Feng LIU ; Meiping LU ; Yifan MENG ; Jichao SHA ; Wenyu SHE ; Lili SHI ; Kuiji WANG ; Jinmei XUE ; Luoying YANG ; Min YIN ; Lichuan ZHANG ; Ming ZHENG ; Bing ZHOU ; Luo ZHANG
Allergy, Asthma & Immunology Research 2020;12(2):176-237
The current document is based on a consensus reached by a panel of experts from the Chinese Society of Allergy and the Chinese Society of Otorhinolaryngology-Head and Neck Surgery, Rhinology Group. Chronic rhinosinusitis (CRS) affects approximately 8% of Chinese adults. The inflammatory and remodeling mechanisms of CRS in the Chinese population differ from those observed in the populations of European descent. Recently, precision medicine has been used to treat inflammation by targeting key biomarkers that are involved in the process. However, there are no CRS guidelines or a consensus available from China that can be shared with the international academia. The guidelines presented in this paper cover the epidemiology, economic burden, genetics and epigenetics, mechanisms, phenotypes and endotypes, diagnosis and differential diagnosis, management, and the current status of CRS in China. These guidelines—with a focus on China—will improve the abilities of clinical and medical staff during the treatment of CRS. Additionally, they will help international agencies in improving the verification of CRS endotypes, mapping of eosinophilic shifts, the identification of suitable biomarkers for endotyping, and predicting responses to therapies. In conclusion, these guidelines will help select therapies, such as pharmacotherapy, surgical approaches and innovative biotherapeutics, which are tailored to each of the individual CRS endotypes.
Adult
;
Asian Continental Ancestry Group
;
Biomarkers
;
China
;
Consensus
;
Diagnosis
;
Diagnosis, Differential
;
Drug Therapy
;
Eosinophils
;
Epidemiology
;
Epigenomics
;
Genetics
;
Humans
;
Hypersensitivity
;
Inflammation
;
International Agencies
;
Medical Staff
;
Neck
;
Phenotype
;
Precision Medicine